Indiplon NDA Expected Mid-Year; Neurocrine Reports Positive Long-Term Data
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Neurocrine Biosciences and Pfizer expect to submit NDAs for immediate- and modified-release formulations of their sleep agent indiplon by June.
You may also be interested in...
Sepracor Looking To Estorra DTC Ads To Wake Up Insomnia Market
Sepracor plans to spend $60 mil. on direct-to-consumer advertising for its insomnia agent Estorra in its first year on the market.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product